TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers reported that a blinded-laboratory reanalysis of a small C-MIC trial found improvements on some exercise measures, while another small study suggested the therapy can be delivered with a subcutaneous implant. The findings are preliminary; a planned 60-person sham-controlled trial is expected to test the approach more rigorously, including in patients with ischemic heart failure.
Researchers presenting at the Heart Failure Society of America annual meeting reported new, preliminary findings on cardiac microcurrent therapy, including a reanalysis of exercise-test data and early results for a subcutaneous implant. The signals may support further study in heart failure, but the small studies do not establish that the therapy works, and a larger sham-controlled trial is still needed.
A post hoc analysis of the C-MIC II trial examined six-month cardiopulmonary exercise test results using a blinded core laboratory. Among 42 participants in the reanalysis, weight-adjusted peak oxygen consumption increased by 2.70 mL/min/kg with C-MIC, according to the report. Other reported measures favored the device: peak metabolic equivalents rose by 1.0 versus 0.1 in controls, and percent-predicted peak VO2 rose by 13.8% versus 0.5%. The metabolic-equivalent and percent-predicted differences had P values of 0.021; the reported absolute peak VO2 comparison did not reach conventional statistical significance (P=0.079).
Dragana Kosevic, of Cardiovascular Institute Dedinje in Belgrade, said the core-lab findings supported functional benefits seen in C-MIC II, while calling for larger randomized studies. The analysis was conducted after the original trial and included only five of its seven sites. The initial trial randomized 65 people with refractory, non-ischemic heart failure with reduced ejection fraction. It reported improvements in ejection fraction, symptoms, functional capacity and quality of life, but peak VO2 had only trended toward improvement in the original site-reported testing.
Researchers also presented early experience with a subcutaneous version of the device in C-MIC III. The generator and lead are placed under the skin, with lead position checked by fluoroscopy during a procedure performed in a catheterization lab under moderate sedation. In a matched comparison, 10 subcutaneous-implant patients were compared with 10 surgical-implant patients and 10 controls from C-MIC II. The researchers reported comparable improvements in ejection fraction, six-minute walking distance and Kansas City Cardiomyopathy Questionnaire scores. The small, non-randomized comparison cannot establish equivalent effectiveness.
A Less Invasive Heart Device
If later trials confirm the early results, a subcutaneous approach could offer a way to deliver C-MIC without surgical epicardial placement. That possibility matters for people with heart failure who remain symptomatic despite treatment, as well as clinicians weighing procedural burden and potential benefit.
For now, the findings are signals for further testing, not evidence that patients should expect improved health or longer survival. The meeting report focused on exercise capacity, heart function and quality-of-life measures. It does not establish effects on hospitalization or mortality, and the reported benefits need confirmation in a stronger trial design.
cardiac microcurrent therapy device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Epicardial Implant to C-MIC III
C-MIC was developed to address changes in the heart muscle’s electrical environment that researchers associate with tissue swelling and impaired left-ventricular function. The proposed mechanism is that microcurrents may shift activated fibroblasts toward a less fibrogenic state, reducing stiffness and improving heart structure and function. This is a proposed biological explanation, not a proven mechanism of clinical benefit.
Earlier C-MIC II work used a surgical epicardial implant and enrolled people with non-ischemic heart failure with reduced ejection fraction. C-MIC III is testing a subcutaneous delivery method. Its earlier six-month results, described at the meeting as improvements from baseline, included a six-point rise in ejection fraction, a 90-meter increase in six-minute walking distance and a 30-point increase in quality-of-life scores. These were small-study findings and do not by themselves show how the device compares with a sham procedure or usual care.
“I am highly skeptical of the magnitude of the benefit that you folks are showing, but I remain actually very enthusiastic about moving this forward.”
— John Teerlink, session discussant
subcutaneous implant heart failure
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Benefit and Device Safety Questions
The size and reliability of C-MIC’s apparent benefit remain uncertain. C-MIC II was small and open-label, and its original exercise-test data were reported by study sites rather than centrally adjudicated. The later core-lab analysis covered 42 people and five of seven sites; it was post hoc, so it cannot replace confirmation in a prospectively designed trial.
The C-MIC III subcutaneous evidence is more limited still: the first-in-human group contained 10 patients, and the matched comparison drew its surgical and control groups from a different trial. Despite matching, the subcutaneous group had more advanced disease at baseline, including lower ejection fractions and greater heart dilation. The available report does not establish how the device performs alongside other implanted cardiac technologies or fully characterize safety in a broader population. Teerlink raised questions about possible interactions with devices such as defibrillators and cardiac resynchronization systems, as well as coronary stents.
heart failure exercise test monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
C-MIC IV Moves Toward Testing
The next major test described at the meeting is C-MIC IV, a planned sham-controlled crossover trial involving 60 people with left-ventricular ejection fractions of 20% to 40%. According to Stefan Simovic of the University of Kragujevac, participants will receive the subcutaneous device, and the study will include both ischemic and non-ischemic heart failure. That would broaden the patient group beyond the earlier studies, which excluded ischemic cardiomyopathy and people with previously implanted devices.
The trial’s results will be needed to judge whether the early measures of function and quality of life reflect a treatment effect beyond expectations, study procedures or other factors. The meeting report did not provide a start date, completion date or detailed safety findings for C-MIC IV. Until those details and results are available, the therapy remains investigational.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is cardiac microcurrent therapy?
C-MIC is an implanted system intended to deliver low-level electrical currents to the heart. Researchers propose that it may affect heart-muscle tissue and function, but the proposed mechanism and clinical benefit still require confirmation.
Did the reanalysis prove that C-MIC improves exercise capacity?
No. The post hoc analysis found that several six-month exercise-test measures favored C-MIC, but it involved 42 people and does not provide definitive proof. The absolute peak VO2 comparison had a P value of 0.079, and the results need confirmation in larger randomized research.
How does the subcutaneous implant differ from the earlier device?
The C-MIC III approach places the generator and lead under the skin, rather than using the surgical epicardial implantation method tested in C-MIC II. Early comparisons involved only 10 subcutaneous-implant patients and cannot establish that the approaches are equally effective or safe.
What will C-MIC IV test?
The planned 60-person sham-controlled crossover trial is expected to study the subcutaneous device in people with ejection fractions of 20% to 40%, including participants with ischemic and non-ischemic heart failure. Its results should provide a more rigorous test than the small studies reported so far.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
